MRS-2541(MRS-2541) - 药物靶点：MetRS_在研适应症：革兰氏阳性细菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

MetRS

作用方式

抑制剂

作用机制

MetRS抑制剂(甲硫氨酰-tRNA合成酶抑制剂)

治疗领域

感染

在研适应症

革兰氏阳性细菌感染

非在研适应症-

原研机构

University of Washington

TSRL, Inc.

在研机构

University of Washington

TSRL, Inc.

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 MRS-2541 相关的临床结果

登录后查看更多信息

100 项与 MRS-2541 相关的转化医学

登录后查看更多信息

100 项与 MRS-2541 相关的专利（医药）

登录后查看更多信息

1

项与 MRS-2541 相关的文献（医药）

2024-12-05·Antimicrobial Agents and Chemotherapy

A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens

Article

作者: Domagala, John ; Buckner, Frederick S. ; Zhang, Zhongsheng ; Gillespie, J. Robert ; Reyna, Dawn ; Fan, Erkang ; Lipka, Elke ; Molasky, Nora M. R.

ABSTRACT New antibiotics are needed to treat gram-positive bacterial pathogens. MRS-2541 is a novel inhibitor of methionyl-tRNA synthetase with selective activity against gram-positive bacteria. The minimum inhibitory concentrations (MICs) against Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus species range from 0.063 to 0.5 µg/mL. Given orally to mice at 50 mg/kg every 8 hours, MRS-2541 shows sustained plasma levels well above these MICs. In the mouse thigh infection model, MRS-2541 decreased methicillin-resistant Staphylococcus aureus and Streptococcus pyogenes bacterial loads to the same degree as linezolid. MRS-2541 is a promising new antibiotic for development against skin and soft tissue infections.

100 项与 MRS-2541 相关的药物交易

登录后查看更多信息